Drug Trial Radar · NCT07753902
Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting Conditions
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Apr 10, 2026
Primary completion
May 18, 2026
Study completion Jun 12, 2026
Sponsor
- Lead sponsor
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial aims to evaluate the bioequivalence of a single oral dose of the test drug ADC118 tablets compared with the reference drugs (ACC017 tablets and emtricitabine/tenofovir alafenamide fumarate tablets \[II\]) under fasting conditions in healthy adult Chinese participants. It will also assess the safety of the test drug. The main questions it aims to answer include: Is the rate and extent of absorption of the test drug ADC118 tablets equivalent to that of the reference drugs? What adverse events will participants experience while taking the study drugs? Researchers will compare the pharmacokinetic profiles of ADC118 tablets with those of the two reference drugs after a single dose. Participants will: Be randomly assigned to one of three treatment sequences (TRR, RTR, or RRT) In each of the three periods, after an overnight fast of at least 10 hours, take a single dose of the test drug (T) or the reference drug (R) with 240 mL of warm water Refrain from drinking water (except for the 240 mL taken with the drug) for 1 hour before and after dosing, and not eat any food for 4 hours after dosing Complete blood sample collection and safety assessments according to the protocol This study plans to enroll 48 healthy participants. It is a single-center, randomized, open-label, three-period crossover trial.
Conditions
- Human Immunodeficiency Virus (HIV) Infection
Interventions
ACC118-TestDrug
Single oral dose of ADC118 tablet, strength: 35 mg ACC017 / 200 mg emtricitabine / 25 mg tenofovir alafenamide fumarate per tablet.
ReferenceDrug
Single oral dose of the following tablets taken together: Two tablets of ACC017, strength: 20 mg/tablet. One tablet of Emtricitabine/Tenofovir Alafenamide Fumarate Tablets (II), strength: 200 mg emtricitabine / 25 mg tenofovir alafenamide fumarate per tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK Parameter: CmaxTime frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose) of each treatment period
- PK Parameter: AUC0-tTime frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose) of each treatment period
- PK Parameter: AUC0-∞Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose) of each treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chizhou People's Hospital
Chizhou, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.